US judge: FTC did not conduct improper probe in Watson/Apotex case, and Bisaro should testify
This article was originally published in Scrip
A federal magistrate judge has determined that, in reviewing the facts provided to the court in the unusual fight between Watson's CEO Paul Bisaro and the US Federal Trade Commission, Watson has not proven its allegations that the FTC overstepped its authority and committed misconduct during its probe of a patent settlement between the generic drug maker and Cephalon. The commission is suing Cephalon on antitrust grounds, claiming reverse payment settlements with generic drug makers on the firm's sleep disorder drug Provigil (modafinil) were illegal and delay generic competition until 2012.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.